U.S. Industrial REITs Stock News

NYSE:FIG
NYSE:FIGSoftware

Figma (FIG) Q1 2026 Narrower Loss Challenges Bearish Margin Narratives

Figma (FIG) opened Q1 2026 with total revenue of US$333.4 million and a basic EPS loss of US$0.27, while trailing 12 month revenue reached US$1.2 billion against a trailing EPS loss of US$3.38 and year on year revenue growth of 41.4%. Over recent quarters, the company has seen revenue move from US$216.9 million in Q4 2024 to US$333.4 million in Q1 2026. Quarterly EPS has swung between a profit of US$0.46 in Q4 2024 and a loss of US$2.72 in Q3 2025 before landing at a loss of US$0.27 this...
NYSEAM:EP
NYSEAM:EPOil and Gas

Empire Petroleum (EP) Q1 Loss Deepens Bearish Narratives On Persistent US$74.5 Million TTM Deficit

Empire Petroleum (EP) opened 2026 with Q1 revenue of about US$5.1 million and a basic EPS loss of US$0.18, while the trailing twelve months show revenue of roughly US$30.3 million and a basic EPS loss of US$2.15. Over recent quarters the company has seen revenue move from US$12.97 million in Q4 2024 to US$9.00 million in Q1 2025 and US$5.10 million in Q1 2026, alongside a shift in quarterly basic EPS losses from US$0.13 to US$0.12 and then US$0.18. This keeps the focus on how efficiently each...
NasdaqGM:HRMY
NasdaqGM:HRMYPharmaceuticals

Earnings Dip, Revenue Growth and Patent Moves Might Change The Case For Investing In Harmony Biosciences (HRMY)

Harmony Biosciences Holdings, Inc. reported past first-quarter 2026 results on May 7, with net income of US$32.49 million, down from US$45.56 million a year earlier, and basic earnings per share from continuing operations of US$0.56 versus US$0.79. Alongside this earnings miss, the company highlighted 17% net product revenue growth, fresh FDA approval for a pediatric cataplexy indication, and active legal efforts to protect WAKIX patents into 2030. We’ll now examine how robust revenue growth...
NYSE:JNJ
NYSE:JNJPharmaceuticals

Assessing Johnson & Johnson (JNJ) Valuation After Earnings Beat Guidance Hike And Ongoing Dividend Growth

Johnson & Johnson (JNJ) just reported quarterly earnings and sales ahead of expectations, supported by both its Innovative Medicines and MedTech segments, while raising 2026 guidance and extending its dividend growth streak to 64 years. See our latest analysis for Johnson & Johnson. Despite the earnings beat and steady dividend record, the stock is trading at US$226.71, with the share price down 5.01% over 30 days and 6.88% over 90 days. The 1-year total shareholder return of 53.99% and...
NYSE:O
NYSE:ORetail REITs

Is Realty Income’s Q1 Beat and Capital Raise Altering The Investment Case For Realty Income (O)?

Earlier in May 2026, Realty Income reported higher first-quarter revenue of US$1,548.73 million and net income of US$311.77 million year over year, modestly lowered full-year 2026 net income per-share guidance, and completed US$99.3 million of share repurchases alongside fresh follow-on and at-the-market equity offerings. The company also advanced its private capital and acquisition agenda by completing a US$1.70 billion cornerstone capital raise, lifting full-year investment guidance to...
NasdaqGS:CECO
NasdaqGS:CECOMachinery

A Look At CECO Environmental (CECO) Valuation After Recent Share Price Momentum

Why CECO Environmental Stock Is On Investors’ Radar CECO Environmental (CECO) has caught investor attention after a strong share price run, with the stock up about 25% over the past month and about 2% over the past 3 months. See our latest analysis for CECO Environmental. That recent 25% 1 month share price return comes after a quieter 3 month move and sits alongside a 35% year to date share price gain and a very large 5 year total shareholder return. Together, these point to strong longer...
NasdaqGS:JD
NasdaqGS:JDMultiline Retail

JD.com (JD) Is Up 6.2% After Big Buyback and Mixed Q1 Earnings - What's Changed

Earlier this week, JD.com reported first-quarter 2026 results showing revenue of CNY 315.69 billion and net income of CNY 5.10 billion, with earnings per share from continuing operations roughly halving year on year. At the same time, JD.com completed a major buyback program repurchasing 227.70 million shares, about 15.87% of its share base, signaling management’s confidence while it invests in automation, AI logistics, and higher-margin services. Next, we’ll examine how JD.com’s strong Q1...
NYSE:INGR
NYSE:INGRFood

Ingredion Tate And Lyle Talks Test Growth Story And Execution Risks

Ingredion (NYSE:INGR) has entered takeover talks to acquire Tate & Lyle in an all cash deal. The potential transaction is valued at about US$3.7b and would combine two major players in sweeteners and specialty food ingredients. The discussions confirm a formal approach, although there is no announced agreement or timeline for completion. For investors watching NYSE:INGR, this move centers on core products like sweeteners, starches, and specialty ingredients that feed into food, beverage,...
NasdaqCM:AEHR
NasdaqCM:AEHRSemiconductor

Will Mixed Q3 Results And A US$60M Equity Raise Change Aehr Test Systems' (AEHR) Narrative

In the past week, Aehr Test Systems reported mixed fiscal third-quarter 2026 results amid sector uncertainty and recent share dilution from a US$60,000,000 equity offering, while insiders filed and amended several Form 4 and Form 144 disclosures including gifts, sales, and potential resale notices. An interesting angle is that these routine yet sizable insider and equity-related filings are intersecting with questions about AI chip demand strength and company backlog, sharpening investor...
NasdaqGS:TCBI
NasdaqGS:TCBIBanks

A Look At Texas Capital Bancshares (TCBI) Valuation As Long Term Returns Contrast With Recent Share Price Softness

Recent performance snapshot Texas Capital Bancshares (TCBI) stock has seen mixed returns recently, with the share price near $95.98 and moves that include a decline over the past month and past 3 months, alongside stronger longer term total returns. See our latest analysis for Texas Capital Bancshares. Short term momentum has faded, with the share price down 7.2% over 3 months, yet the 1 year total shareholder return of 26.6% and 3 year total shareholder return of 95.6% show a stronger longer...
NasdaqGS:WIX
NasdaqGS:WIXIT

Is Wixcom (WIX) Now An Opportunity After Sharp Share Price Pullback

If you are wondering whether Wix.com at US$52.71 is starting to look like value or still carries too much risk, the recent share price performance gives you plenty to think about. The stock has fallen 34.4% over the past week, 17.4% over the last month, 47.8% year to date, 71.2% over one year, 34.7% over three years, and 78.7% over five years, which may change how you think about its potential and the risks involved. Recent coverage around Wix.com has focused on how the stock's sharp...
NasdaqCM:ALMU
NasdaqCM:ALMUSemiconductor

Aeluma (ALMU) Q3 Loss Of US$1.8 Million Tests Bullish Profitability Narratives

Aeluma (NasdaqCM:ALMU) has just posted its Q3 2026 numbers, reporting revenue of US$1.2 million and a loss of US$1.8 million, or EPS of US$0.10. This sets a cautious tone for shareholders at the current US$26.65 share price. Over recent quarters the company has reported revenue between US$1.3 million and US$1.6 million, while EPS has shifted from a profit of US$0.12 in Q3 2025 to losses of around US$0.09 to US$0.24 per share. This has kept margins under clear pressure and made profitability...
NasdaqCM:LQDA
NasdaqCM:LQDAPharmaceuticals

Evaluating Liquidia (LQDA) Valuation After Strong Share Price Momentum And YUTREPIA Launch Progress

Recent share performance and business overview Liquidia (LQDA) has drawn fresh attention after recent trading, with the stock’s moves prompting investors to reassess how its rare cardiopulmonary drug portfolio and clinical programs align with their own risk and return expectations. See our latest analysis for Liquidia. Recent trading sits within a much stronger backdrop, with a 30 day share price return of 53.19% and a 1 year total shareholder return of 207.25%. This points to powerful...
NasdaqGM:AXSM
NasdaqGM:AXSMPharmaceuticals

A Look At Axsome Therapeutics (AXSM) Valuation After AUVELITY Alzheimer’s Agitation Launch Plans And Earnings Update

Axsome Therapeutics (AXSM) is back in focus after detailing plans to launch AUVELITY for Alzheimer’s disease agitation in June, supported by a larger sales force and expectations of broad Medicare Part D coverage. See our latest analysis for Axsome Therapeutics. The June AUVELITY launch plan for Alzheimer’s agitation and recent first quarter 2026 earnings have arrived alongside strong momentum, with a 30 day share price return of 26.11% and a one year total shareholder return of 116.63%. If...
NasdaqCM:SLS
NasdaqCM:SLSBiotechs

SELLAS Nears Key AML Data As Dual Trials Shape High-Risk Outlook

SELLAS Life Sciences Group (NasdaqCM:SLS) is nearing the pivotal Phase 3 data readout for galinpepimut-S in the REGAL trial for acute myeloid leukemia (AML). The company has also initiated a Phase 2 trial of its CDK9 inhibitor SLS009 in newly diagnosed, high-risk AML patients. These clinical milestones mark a key moment for the company’s AML program and broader oncology pipeline. SELLAS Life Sciences Group focuses on late-stage, oncology-focused drug candidates, with galinpepimut-S and...
NasdaqGS:CNXC
NasdaqGS:CNXCProfessional Services

Assessing Concentrix (CNXC) Valuation As AI Concerns And Webhelp Leverage Pressure Investor Sentiment

Concentrix (CNXC) is back in focus as investors weigh its upcoming appearance at the Needham Technology, Media, & Consumer Conference in light of ongoing worries about AI disruption, softer growth trends, and higher leverage from the Webhelp acquisition. See our latest analysis for Concentrix. The recent share price tells a cautious story, with Concentrix at US$23.42 after a 1 month share price return down 17.19% and year to date share price return down 43.17%. This mirrors a 1 year total...
NasdaqCM:TRON
NasdaqCM:TRONLeisure

How Investors Are Reacting To Tron (TRON) Returning To Profitability On Modest Q1 2026 Sales Growth

Tron Inc. reported first-quarter 2026 results, with sales of US$1.18 million versus US$1.09 million a year earlier and net income of US$21.63 million compared with a net loss in the prior-year period. This shift from a loss per share to positive basic earnings per share from continuing operations highlights a sharp improvement in Tron's profitability profile. We will now examine how Tron's return to profitability in the latest quarter shapes the company's broader investment narrative and...
NasdaqGM:OMER
NasdaqGM:OMERPharmaceuticals

Omeros (OMER) Q1 Profit Of US$51.2 Million Tests One Off Gain Narrative

Omeros (OMER) opened 2026 with Q1 revenue of US$9.9 million and basic EPS of US$0.71, alongside net income from continuing operations of US$51.2 million, setting a clear earnings focused tone for the quarter. Over recent periods, the company has seen quarterly revenue move from US$0 to US$9.9 million while quarterly EPS has ranged from a loss of US$0.65 to a gain of US$1.13, giving investors a wide band of outcomes to weigh as they assess how much of the latest profit is repeatable versus...
NasdaqGM:CRML
NasdaqGM:CRMLMetals and Mining

Is Critical Metals (CRML) Quietly Redrawing Western Hafnium Supply Chains With Its Greenland Expansion?

Earlier this month, Critical Metals Corp. received formal approval from the Government of Greenland to acquire a 70% stake in 60 North Greenland ApS, advancing control over key land and assets linked to its Tanbreez rare earth and hafnium project. This approval, together with plans for a Romanian hafnium refinery geared to EU, NATO and US customers, underlines Critical Metals’ role in efforts to reshape Western supply chains for this tightly constrained metal. We’ll now examine how...
NYSE:DOCS
NYSE:DOCSHealthcare Services

Doximity (DOCS) Margin Compression Challenges Bullish AI Growth Narratives After FY 2026 Results

Doximity (DOCS) has just wrapped up FY 2026 with Q4 revenue of US$145.4 million and basic EPS of US$0.10, while trailing twelve month revenue stood at US$644.9 million and EPS at US$1.05. Over recent periods, the company has seen quarterly revenue move between US$138.3 million and US$185.1 million, with basic EPS ranging from US$0.28 to US$0.40, setting the backdrop for a trailing net profit margin that sits at 30.4% versus 39.1% a year earlier. For investors, the latest earnings print is...
NYSE:KNSL
NYSE:KNSLInsurance

How Investors Are Reacting To Kinsale Capital Group (KNSL) Earnings Beat And Higher Dividend Announcement

Kinsale Capital Group recently declared a US$0.25 per-share cash dividend, payable on June 11, 2026 to shareholders of record on May 28, 2026, while also reporting first-quarter 2026 earnings that exceeded analyst expectations. The company’s 10-year streak of dividend increases, including very large dividend growth over the past year, highlights a sustained focus on shareholder returns alongside its specialty excess and surplus insurance operations. We’ll now examine how Kinsale’s...
NYSE:BIRK
NYSE:BIRKLuxury

Birkenstock Holding (BIRK) Net Margin Jump To 16.3% Tests Bearish Capacity Concerns

Birkenstock Holding (NYSE:BIRK) has just posted Q2 2026 results with revenue of €618.3 million and basic EPS of €0.45, set against trailing twelve month revenue of about €2.2 billion and EPS of €1.93. This coincided with net profit margin moving to 16.3% from 12.9% and earnings growth of 40.9% over the past year. Over recent quarters, the company has seen revenue move from €574.3 million and EPS of €0.56 in Q2 2025 to €618.3 million and €0.45 in Q2 2026. At the same time, trailing EPS has...
NasdaqGS:EA
NasdaqGS:EAEntertainment

Is It Too Late To Consider Electronic Arts (EA) After Its Strong 1 Year Share Price Run?

Wondering if Electronic Arts at around US$200.78 is still a reasonable entry point or if the easy gains are already behind it? This article walks through what the current price could imply about value. The stock is roughly flat over the past week, has declined about 1% over the past month and is down 1.8% year to date. It has delivered a 34.8% return over 1 year, 61.6% over 3 years and 45.4% over 5 years. Recent attention on big gaming franchises, ongoing content updates and the broader...
NYSE:MUSA
NYSE:MUSASpecialty Retail

Assessing Murphy USA (MUSA) Valuation After Strong Recent Share Price Momentum

Murphy USA (MUSA) has drawn investor attention after recent share price moves, with the stock last closing at US$576.20 and showing mixed short term returns alongside relatively stronger performance over the past 3 months and year. See our latest analysis for Murphy USA. While the share price has eased in the very short term, the 30 day share price return of 15.60% and strong multi year total shareholder returns, including 322.33% over five years, point to momentum that has built over time as...